Advance in Predicting Hemorrhage Transformation after Intravenous Thrombosis

Abstract

Abstract:

This article reviews the risk factors of complications of symptomatic intracerebral hemorrhage(SICH) after intravenous thrombolysis and its related predictive models and also compares the characteristics and clinical values of those models with the aim to facilitate obtaining the reliable therapy strategies for acute ischemic stroke and choosing the quantitative assisted instruments for those who required intravenous thrombolysis in clinical practice.

Key words: Stroke, Ischemic; Stroke, Ischemic; Intravenous thrombolysis; Symptomatic intracerebral hemorrhage

摘要：

本文对急性缺血性卒中静脉溶栓治疗后出现症状性脑出血并发症的危险因素及相关预测模型进行综述，通过比较不同的预测模型的特点及其应用价值，以期为临床实践获得可靠的指导急性缺血性卒中治疗决策和选择合适静脉溶栓病例的量化辅助工具

关键词: 卒中; 缺血性; 静脉溶栓; 症状性脑出血

HUANG Qiang, WU Jian. Advance in Predicting Hemorrhage Transformation after Intravenous Thrombosis[J]. Chinese Journal of Stroke, 2013, 8(03): 190-196.

黄镪，武剑. 静脉溶栓后出血转化的风险预测的研究进展[J]. 中国卒中杂志, 2013, 8(03): 190-196.

References

[No authors listed]. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group[J]. N Engl J Med, 1995, 333:1581-1587.

Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke(ECASS II). Second European-Australasian Acute Stroke Study Investigators[J]. Lancet, 1998, 352:1245-1251.

Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study(SITS-MOST):an observational study[J]. Lancet, 2007, 369:275-282.

Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med, 2008, 359:1317-1329.

Brown DL, Barsan WG, Lisabeth LD, et al. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke[J]. Ann Emerg Med, 2005, 46:56-60.

Libman R, Kwiakowski T, Lyden P, et al. Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome[J]. J Stroke Cerebrovasc Dis, 2005, 14:50-54.

Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue:asymptomatic or symptomatic?[J]. Stroke, 2001, 32:1330-1335.

Strbian D, Sairanen T, Meretoja A, et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis[J]. Neurology, 2011, 77:341-348.

Gumbinger C, Gruschka P, Bottinger M, et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage[J]. Stroke, 2012, 43:240-242.

Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase:Safe Implementation of Treatments in Stroke(SITS) symptomatic intracerebral hemorrhage risk score[J]. Stroke, 2012, 43:1524-1531.

Menon B K, Saver JL, Prabhakaran S, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator[J]. Stroke, 2012, 43:2293-2299.

Strbian D, Engelter S, Michel P, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis:the SEDAN score[J]. Ann Neurol, 2012, 71:634-641.

Saposnik G, Raptis S, Kapral M K, et al. The iScore predicts poor functional outcomes early after hospitalization for an acute ischemic stroke[J]. Stroke, 2011, 42:3421-3428.

Saposnik G, Kapral MK, Liu Y, et al. IScore:a risk score to predict death early after hospitalization for an acute ischemic stroke[J]. Circulation, 2011, 123:739-749.

Saposnik G, Fang J, Kapral MK, et al. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke[J]. Stroke, 2012, 43:1315-1322.

Lou M, Safdar A, Mehdiratta M, et al. The HAT Score:a simple grading scale for predicting hemorrhage after thrombolysis[J]. Neurology, 2008, 71:1417-1423

Cucchiara B, Tanne D, Levine SR, et al. A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2008, 17:331-333.

Prabhakaran S, Rivolta J, Vieira JR, et al. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke[J]. Arch Neurol, 2010, 67:559-563.

Seet RC, Zhang Y, Moore SA, et al. Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis[J]. Stroke, 2011, 42:2333-2335.

Ruecker M, Matosevic B, Willeit P, et al. Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis[J]. Neurology, 2012, 79:31-38.

Vergouwen MD, Casaubon LK, Swartz RH, et al. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator[J]. Stroke, 2011, 42:1041-1045.

De Marchis GM, Jung S, Colucci G, et al. Intracranial hemorrhage, outcome, and mortality after intra-arterial therapy for acute ischemic stroke in patients under oral anticoagulants[J]. Stroke, 2011, 42:3061-3066.

Xian Y, Liang L, Smith EE, et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator[J]. JAMA, 2012, 307:2600-2608.

Engelter ST, Soinne L, Ringleb P, et al. IV thrombolysis and statins[J]. Neurology, 2011, 77:888-895.

Nardi K, Engelter S, Strbian D, et al. Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia[J]. Neurology, 2012, 79:1101-1108.

Qureshi AI, Chaudhry SA, Hassan AE, et al. Thrombolytic treatment of patients with acute ischemic stroke related to underlying arterial dissection in the United States[J]. Arch Neurol, 2011, 68:1536-1542.

Edgell RC, Vora NA. Neuroimaging markers of hemorrhagic risk with stroke reperfusion therapy[J]. Neurology, 2012, 79:S100-S104.

Singer OC, Kurre W, Humpich MC, et al. Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-ASPECTS[J]. Stroke, 2009, 40:2743-2748.

Lin K, Zink WE, Tsiouris AJ, et al. Risk assessment of hemorrhagic transformation of acute middle cerebral artery stroke using multimodal CT[J]. J Neuroimaging, 2012, 22:160-166.

Lansberg MG, Thijs VN, Bammer R, et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke[J]. Stroke, 2007, 38:2275-2278.

Audebert HJ, Singer OC, Gotzler B, et al. Postthrombolysis hemorrhage risk is affected by stroke assessment bias between hemispheres[J]. Neurology, 2011, 76:629-636.

Campbell BC, Christensen S, Butcher KS, et al. Regional very low cerebral blood volume predicts hemorrhagic transformation better than diffusion-weighted imaging volume and thresholded apparent diffusion coefficient in acute ischemic stroke[J]. Stroke, 2010, 41:82-88.

Aviv RI, D'Esterre CD, Murphy BD, et al. Hemorrhagic transformation of ischemic stroke:prediction with CT perfusion[J]. Radiology, 2009, 250:867-877.

Neumann-Haefelin T, Hoelig S, Berkefeld J, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke[J]. Stroke, 2006, 37:2463-2466.

Hjort N, Wu O, Ashkanian M, et al. MRI detection of early blood-brain barrier disruption:parenchymal enhancement predicts focal hemorrhagic transformation after thrombolysis[J]. Stroke, 2008, 39:1025-1028.

Saqqur M, Tsivgoulis G, Molina CA, et al. Symptomatic intracerebral hemorrhage and recanalization after IV rt-PA:a multicenter study[J]. Neurology, 2008, 71:1304-1312.

Jickling GC, Sharp FR. Blood biomarkers of ischemic stroke[J]. Neurotherapeutics, 2011, 8:349-360.

Nafria C, Fernandez-Cadenas I, Mendioroz M, et al. Update on the serum biomarkers and genetic factors associated with safety and efficacy of rt-PA treatment in acute stroke patients[J]. Stroke Res Treat, 2011, 2011:182783.

Laskowitz DT, Kasner SE, Saver J, et al. Clinical usefulness of a biomarker-based diagnostic test for acute stroke:the Biomarker Rapid Assessment in Ischemic Injury(BRAIN) study[J]. Stroke, 2009, 40:77-85.

Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes:novel derivation method and application to thrombolytic therapy for acute stroke[J]. Arch Neurol, 2004, 61:1066-1070.

Saver JL. Hemorrhage after thrombolytic therapy for stroke:the clinically relevant number needed to harm[J]. Stroke, 2007, 38:2279-2283.

[1]	WANG Xiaorui, LUO Song, ZOU Liangyu, QU Hongdang, CUI Xue, ZHAO Yujie. Value of Eosinophil-to-Monocyte Ratio in Predicting the Prognosis of Patients with Acute Ischemic Stroke Receiving Intravenous Thrombolysis [J]. Chinese Journal of Stroke, 2024, 19(9): 1025-1033.
[2]	DING Zeyu, LI Guangshuo, ZHAO Xingquan. Relationship between High Levels of Fasting Blood Glucose and Functional Outcome after Intravenous Thrombolysis in Patients with Ischemic Stroke [J]. Chinese Journal of Stroke, 2024, 19(3): 293-298.
[3]	ZHENG Jianhua, CUI Yanling, CAO Ying, DAI Jianwu. A Case Report of Capsule Warning Syndrome Treated with Tirofiban Bridging Dual Antiplatelet Therapy after Intravenous Thrombolysis with Alteplase [J]. Chinese Journal of Stroke, 2024, 19(3): 326-330.
[4]	WANG Yongjun, XIONG Yunyun, LI Guangshuo, CAO Zhixin, WANG Wenjie, YAN Ran, WANG Liyuan, LU Zhengzhao, HAO Manjun. Highlights in Stroke in 2023 [J]. Chinese Journal of Stroke, 2024, 19(1): 1-21.
[5]	YANG Jiaxin, HE Chunyu, LIU Lei, CHEN Wenbo, XIE Yan. Prediction Models of Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke: A Systematic Review [J]. Chinese Journal of Stroke, 2024, 19(1): 76-86.
[6]	Chinese Stroke Association. CSA Declaration of Next-generation Reperfusion Therapy for Ischemic Stroke [J]. Chinese Journal of Stroke, 2023, 18(12): 1465-1466.
[7]	ZONG Lixia, GU Hongqiu, YANG Xin, JIANG Yingyu, LI Zixiao, WANG Chunjuan. Trend of Intravenous Thrombolysis and a Comparative Analysis of In-hospital Outcomes of Intravenous Thrombolysis with Alteplase or Urokinase in Acute Ischemic Stroke in China from 2016 to 2022 [J]. Chinese Journal of Stroke, 2023, 18(10): 1202-1208.
[8]	LU Yan, YANG Baorong, HUANG Xiangping, YANG Guangui, CHEN Shengwen, LI Jianrong, ZENG Xiaoming. MRI-Guided Thrombolysis beyond Time Window in Acute Ischemic Stroke in a County-Level Hospital: A Case-Control Study [J]. Chinese Journal of Stroke, 2022, 17(12): 1321-1326.
[9]	CAO Shuangshuang, ZHANG Xiaoyan, WANG Jianwei, ZHAO Lei, CHEN Hongbing, WANG Mingyu. The Related Factors of Early Neurological Deterioration after Intravenous Thrombolysis in Patients with Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2021, 16(12): 1253-1258.
[10]	ZHANG Xin-Miao, WANG Chun-Juan, YANG Xin, GU Hong-Qiu, JIANG Ying-Yu, WANG Yi-Long, ZHAO Xing-Quan, LI Zi-Xiao, WANG Yong-Jun. Safety of Intravenous Thrombolysis in Acute Ischemic Stroke Patients with Antithrombotic Therapy before Stroke Onset [J]. Chinese Journal of Stroke, 2021, 16(11): 1110-1114.
[11]	WANG Zhen, XU Wei, HE Guo-Hua, HU Jue, FENG Tie-Qiao, TONG Yang-Ping, XU Gui-Lan, XIAO Hui, YI Hai-Bo, SONG Zhi. Clinical Features and Prognosis of Remote Parenchymal Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2021, 16(07): 680-686.
[12]	CHEN Ying, GAO Ya-Li, LIN Fang-Ju, JIA Wei-Hua. Clinical Analysis and Literature Review of Intravenous Thrombolysis in Acute Ischemic Stroke with Active Malignancy [J]. Chinese Journal of Stroke, 2021, 16(02): 130-135.
[13]	HUANG Li-Hong, LIU Guang-Wei. A Review on Risk Factors Associated with Poor Prognosis after Intravenous Thrombolysis in Ischemic Stroke Patients [J]. Chinese Journal of Stroke, 2020, 15(12): 1352-1359.
[14]	LIU Hui-Hui, JIANG Qian-Mei, DAI Jing,LIU Chun-Feng. Advances in Intravenous Thrombolysis for Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2020, 15(09): 934-941.
[15]	WU Ya, LI Wei. Status of Intravenous Thrombolysis for Acute Perforating Artery Infarcts [J]. Chinese Journal of Stroke, 2020, 15(09): 942-946.